AOD-9604 + MOTS-c Stack: When to Pick One Over the Stack

Is there any evidence for stacking AOD-9604 with MOTS-c?

The case for stacking rests on rodent pharmacology: AOD-9604 increased fat-tissue lipolytic activity in obese rats, and MOTS-c activated AMPK signaling in mice [3][4]. Neither compound has been given to people in a form that produced a measured metabolic benefit in a controlled trial.

A 2026 review of approved and unapproved peptides marketed for musculoskeletal injuries and athletic performance, which covers both AOD-9604 and MOTS-c, concluded that many unapproved peptides show favorable results in animal models while rigorous human safety data are scarce and serious harm is possible [5].

What AOD-9604 is and what it has shown

AOD-9604 is human growth hormone amino acids 177 to 191 with an extra tyrosine added at the N-terminus, 16 amino acids in total, which is why it is also called hGH fragment 176-191. It is not full-length growth hormone [6][1]. An Australian company, Metabolic Pharmaceuticals, developed it as an anti-obesity candidate, with phase IIa trials underway by February 2002; it never reached approval and the obesity program was later dropped [7][1].

Animal work. In obese Zucker rats, oral AOD9604 at 500 microgram/kg/day for 19 days cut body-weight gain to 15.8 g versus 35.6 g in controls, raised fat-tissue lipolytic activity, and, unlike chronic intact growth hormone, did not worsen insulin sensitivity on euglycemic clamp [3]. In obese mice, 14 days of intraperitoneal AOD9604 reduced body weight and body fat, and the long-term effect was absent in mice lacking the beta-3 adrenergic receptor [8]. A 2026 review adds that preclinical work found no growth-hormone-receptor binding [1].

Human work. The main human test described in a 2026 review is a 24-week oral obesity study with 534 enrolled and 502 randomized that failed to show a significant benefit on its primary weight-loss endpoint [1]. That conclusion rests on sponsor-reported phase 2 results; no peer-reviewed efficacy paper for the trial exists [1].

No approved dose. The human trial tested an oral drug candidate; no efficacy trial of the injected product sold online has been identified [1].

The GRAS claim. FDA's GRAS Notice Inventory contains no AOD-9604 notice. The 'conditional GRAS' conclusion the developer announced in 2012 came from a panel it commissioned, not from FDA, and GRAS is a food-ingredient concept that would not make an injectable lawful as a drug [9].

What MOTS-c is and what it has shown

MOTS-c stands for mitochondrial open reading frame of the 12S rRNA-c: a 16-amino-acid peptide, molecular weight about 2174.6 g/mol, encoded in mitochondrial DNA and first reported in 2015 [2][4]. FDA treats the free base and the acetate salt as different bulk substances [2].

Mouse data. In mice on a high-fat diet, injected MOTS-c at 0.5 mg/kg/day for 8 weeks produced roughly 20% lower body weight, and in one experiment a late-life schedule (15 mg/kg three times weekly from 23.5 months of age) extended median lifespan from 912 to 970 days [2]. Effects appear to involve AMPK signaling and reduced one-carbon metabolism, though FDA notes the molecular targets are unknown and no dose-response relationships were assessed [2].

Human data. FDA's July 2026 evaluation searched PubMed, Embase and the Cochrane library and found no clinical study in which MOTS-c was given to a person; the 12 papers the nominator cited were not clinical studies [2]. What human research exists measured the body's own MOTS-c. Exercise induced endogenous MOTS-c expression in skeletal muscle and in circulation [10], and in a randomized study of 30 healthy adults (10 endurance, 10 resistance, 10 control), plasma MOTS-c showed only a trend to rise after endurance exercise and was not related to fitness [11]. Another paper proposed that a MOTS-c gene variant specific to Northeast Asian populations might help explain Japanese longevity; that is a hypothesis about a gene variant, not a drug trial [12].

A pharmacokinetic problem. MOTS-c is quickly broken down in human blood in vitro, which raises the question of whether injecting it can produce active levels in a person [2].

No approved dose. The products nominated to FDA were 5 mg and 10 mg subcutaneous injections, and the rodent doses used in research (0.5 to 15 mg/kg) cannot be converted into a human dose [2].

So when does picking one over the stack make sense?

On the current record, not on grounds of effect. Where the two genuinely diverge is regulatory and anti-doping status.

FDA's safety list. Both peptides sit in the 'nominated but withdrawn' table on FDA's page about bulk substances that may present significant safety risks. That table holds substances previously in category 2 whose nominators withdrew them, and removal from category 2 was not a finding that either is safe [13]. For AOD-9604, FDA cited immunogenicity risk from peptide impurities and characterization problems, no or only limited safety information, and serious adverse events that may be associated with it though causality is not clear [13]. For MOTS-c, FDA cited the lack of human exposure data on any route and immunogenicity risk from aggregation and impurities [13].

No category covers either. Neither peptide appears in any of the three categories on FDA's list for state-licensed pharmacies and physicians or on FDA's list for outsourcing facilities, so FDA's category 1 enforcement-discretion policy does not cover them [14][15][16].

Where they diverge. HHS's draft enforcement-discretion policy for six peptides, filed 28 October 2026, names MOTS-c (acetate, subcutaneous or intramuscular injection) and does not name AOD-9604 [17][18]. In it, HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility or licensed physician compounding with MOTS-c acetate if the policy's conditions are met. It is a draft, not an approval; the notice says it does not establish any rights for any person and is not binding on HHS or the public [17]. Separately, FDA's Pharmacy Compounding Advisory Committee voted on 23 July 2026 in favor of adding MOTS-c to the bulks list, against the recommendation of FDA staff, who cited no human safety or effectiveness data, no animal toxicity studies, and poor characterization. That vote is advice only, MOTS-c is not on the list, and adding it would take formal rulemaking [19][2].

Safety record for each

AOD-9604. FDA states that it identified serious adverse events that may be associated with AOD-9604, though causality is not clear, and gives no details [13]. A 2026 review concludes that human evidence is limited and largely short-term [1].

MOTS-c. FDA's stated concern for injection is immunogenicity from aggregation and peptide-related impurities; the peptide has 16 amino acids and no immunogenicity data exist [2]. FDA also found no animal toxicity studies and no pharmacokinetic data in humans or in live animals, and a search of its adverse-event database through 9 March 2025 retrieved no MOTS-c reports [2].

If you compete under anti-doping rules

WADA names AOD-9604 and hGH 176-191 in S2.2.3 (growth hormone fragments) and MOTS-c in S4.4.1 (AMPK activators). Both are prohibited at all times, in and out of competition, and both S2 and S4.4 substances are non-Specified Substances [20]. Both appear on the 2026 List, in force since 1 January 2026, and remain on the 2027 tracked-changes version dated 26 August 2026 [20][21]. Anti-doping scientists have published urine detection methods for AOD-9604 and its stable metabolite [6].